AJP Asia Intelligence Agency

Lotte Biologics Celebrates Opening of First Factory in Songdo


"Lotte Biologics has laid the foundation to enhance South Korea's large-scale production capacity in the biotech industry, beyond just the completion of the new production facility."
 
Shin Yoo-yeol, CEO of Lotte Biologics, made this statement during the opening ceremony of the first factory held at the Songdo Bio Campus on the morning of November 18. He emphasized, "We will become a contract development and manufacturing organization (CDMO) partner that walks alongside our customers in the long term, based on quality, technology, and trust that customers can feel." This was Shin's first official event after being promoted to president of Lotte Holdings just two days prior.

Lotte Biologics has established a large-scale production base in South Korea just four years after entering the biotech business. The opening ceremony was attended by over 300 people, including Shin Dong-bin, chairman of Lotte Group, Park James, CEO of Lotte Biologics, and Park Chan-dae, mayor of Incheon.

During the ceremony, Chairman Shin expressed hope that the opening of the first factory at the Songdo Bio Campus would serve as a significant turning point to enhance the competitiveness of South Korea's biotech industry beyond the growth of Lotte Group, lending support to his son, CEO Shin, who leads the group's biotech business.
 
The Songdo Factory, which began construction in March 2024, is a production facility with a capacity of 120,000 liters, equipped with eight stainless steel bioreactors of 15,000 liters each. The total floor area is approximately 100,000 square meters. Automation equipment has been applied since the design stage. The culture medium is produced on the top floor and sent down to the production line below, reducing the raw material transfer route. The logistics warehouse, which has 6,030 storage spaces, employs robots for the inbound and outbound logistics of raw materials and supplies. The central control room allows for real-time monitoring of the operational status of key facilities.

The factory is currently in the final stages of preparation for commercial production, including equipment qualification and process validation. Full-scale production is set to begin next year, with production volumes already secured. On November 17, a day before the opening, Lotte Biologics signed its first large-scale commercial production contract with a global pharmaceutical company for the Songdo Factory. The details of the contract, including the partner and product, have not been disclosed. By securing production volumes before completion, the company has alleviated initial operational rate burdens.

Lotte Group has identified CDMO as a new growth engine and established Lotte Biologics in June 2022. In December of the same year, it acquired Bristol Myers Squibb's Syracuse plant in New York for 160 million dollars (approximately 208 billion won). The company aims to actively absorb the demand for global supply chain restructuring, including the Biodefense Act, by promoting a 'Dual-Site' strategy that connects the Syracuse plant, which has strengths in clinical volumes and antibody-drug conjugates (ADCs), with the large-scale commercial production base at the Songdo Factory.

Lotte Biologics also plans to further increase production capacity in Songdo. The company intends to build additional factories 2 and 3 in Songdo, expanding domestic production capacity to 360,000 liters. Songdo is already home to production facilities from major domestic biotech companies, including Samsung Biologics and Celltrion, making it a hub for South Korea's leading biotech firms.

Park James, CEO of Lotte Biologics, emphasized, "We will grow into a company that contributes to the health of patients and a better life for humanity, based on our new mission of relentless pursuit of perfection and genuine commitment to life."
 




* This article has been translated by AI.